Sign inJoin waitlistJoin the waitlist

RC

Roger Cohen

Fellowship Program Director, Hematology-Oncology · University of Pennsylvania Health System

Credentials: · · · · ·

History

Hematology-Oncology Fellowship · University of Pennsylvania Health System
Present
Perelman School of Medicine at the University of Pennsylvania
Present
University of Pennsylvania Health System
Present

National Cancer Institute
1986–1988
Mount Sinai Medical Center
1983–1986
Mount Sinai Medical Center
1980–1983
Harvard Medical School
1976–1980
Harvard College (magna cum laude), 1976.
1972–1976

Research

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
New England Journal of Medicine · 2006 · 3,932 citations
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and…
The Lancet Oncology · 2010 · 1,461 citations
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
New England Journal of Medicine · 2007 · 1,268 citations

Charu Aggarwal
77 papers · 1 as a fellow
Corey Langer
71 papers
LS
Lova Sun
47 papers · 5 as a fellow
Joshua Bauml
46 papers · 1 as a fellow
Aditi Singh
38 papers · 12 as a fellow
Melina Marmarelis
31 papers · 2 as a fellow
Alexander Lin
30 papers
John Lukens
28 papers · 2 as a fellow
Christine Ciunci
25 papers
Gregory Weinstein
25 papers
Steven Feigenberg
24 papers · 2 as a resident
Ara Chalian
22 papers

Grants

Abramson Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.5M · University of Pennsylvania
1997–2025
Chromatin Structure and Globin Gene Expression in Melc
National Cancer Institute · F32
Contact PI · $18.5K · Sloan-Kettering Inst Can Research
1984

Clinical trials

GFRα4 CAR T Cells in MTC Patients
Principal investigator · Active not recruiting · Phase 1
University of Pennsylvania
2021–2039
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2020–2026
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Principal investigator · Completed · Phase 1, Phase 2
Codiak BioSciences
2020–2022
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Heat Biologics
2014–2018